(IN BRIEF) Sanofi’s Sarclisa has been approved by the European Union as the first anti-CD38 therapy in combination with VRd to treat adult patients with newly diagnosed multiple myeloma who are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback